Senti Biosciences Inc

SNTI

Company Profile

  • Business description

    Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

  • Contact

    2 Corporate Drive
    First Floor
    South San FranciscoCA94080
    USA

    T: +1 650 239-2030

    https://www.sentibio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    48

Stocks News & Analysis

stocks

We remove our Moat Rating from ASX listed share

Despite a surging share price a weakening competitive position causes a reassessment of our view.
stocks

Best sustainable companies to own in 2026

We believe these companies’ strong ESG management practices give them a long-term advantage.
stocks

New data centre deal for ASX listed REIT

New parternship adds to a growing data centre pipeline in fiscal 2026.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,034.702.20-0.02%
CAC 408,200.114.900.06%
DAX 4024,788.75249.411.02%
Dow JONES (US)48,911.69529.301.09%
FTSE 1009,984.1032.960.33%
HKSE26,347.248.770.03%
NASDAQ23,407.76172.130.74%
Nikkei 22551,832.801,493.322.97%
NZX 50 Index13,587.2338.810.29%
S&P 5006,904.6046.130.67%
S&P/ASX 2008,728.602.600.03%
SSE Composite Index4,023.4254.581.38%

Market Movers